Cronos Group Past Earnings Performance
Past criteria checks 0/6
Cronos Group's earnings have been declining at an average annual rate of -54.2%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 33.2% per year.
Key information
-54.2%
Earnings growth rate
-57.1%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 33.2% |
Return on equity | -6.4% |
Net Margin | -80.1% |
Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Cronos Stock: Attractive Now With Cannabis Legalization In Germany
Mar 04Cronos Group: Flush With Cash And Trading Below Book Value
Feb 11Cronos Group GAAP EPS of -$0.05 beats by $0.01, revenue of $23.1M misses by $5.25M
Aug 09Cronos Group: Too Much Cash, Too Soon - Making The Bear Case
Aug 01Cronos Group: High Hurdles
May 11Cronos Earnings: Cannabis Stock With 65% Net Cash And 51% Revenue Growth
Mar 01Cronos Group Late-Filed Q3-2021 Earnings Show Revenues From Synthetic Cannabinoids
Feb 22Cronos Group: Still No Reason To Own
Jan 22Cronos Group Strategic Investor Altria May Be About To Buy The Balance
Nov 08After Cronos Finally Invests In U.S. Cannabis, Is The Stock A Buy?
Aug 30Is Cronos Stock Worth Buying? Probably, But Patience Remains A Requirement
Jul 12Cronos Group stock rises 2.6% with acquisition of 10.5% stake in PharmaCann
Jun 14Cronos Group: Still Hasn't Launched
May 09Cronos Group Q1 Earnings Preview
May 06Cronos: The Most Confusing Cannabis Stock
Apr 28Cronos: Sitting On Your Hands Is Not A Winning Strategy
Jan 03Cronos Group (CRON) Investor Presentation - Slideshow
Nov 24Cronos Is A Buy With Increasing Revenues
Nov 18Cronos shares rise 5% on solid Q3 beat; top-line +96% boosted by advancement in Canadian/Israeli market
Nov 05Cronos: Failure To Launch
Nov 03Revenue & Expenses BreakdownBeta
How Cronos Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 87 | -70 | 81 | 6 |
30 Sep 23 | 91 | -115 | 95 | 7 |
30 Jun 23 | 86 | -146 | 99 | 8 |
31 Mar 23 | 87 | -155 | 98 | 11 |
31 Dec 22 | 87 | -155 | 101 | 13 |
30 Sep 22 | 91 | -213 | 109 | 17 |
30 Jun 22 | 91 | -102 | 130 | 21 |
31 Mar 22 | 85 | -263 | 145 | 22 |
31 Dec 21 | 65 | -127 | 122 | 22 |
30 Sep 21 | 66 | -373 | 154 | 24 |
30 Jun 21 | 57 | -381 | 142 | 22 |
31 Mar 21 | 51 | -310 | 132 | 21 |
31 Dec 20 | 47 | -72 | 130 | 20 |
30 Sep 20 | 37 | 101 | 126 | 19 |
30 Jun 20 | 31 | 636 | 116 | 17 |
31 Mar 20 | 29 | 929 | 107 | 16 |
31 Dec 19 | 24 | 1,167 | 116 | 12 |
30 Sep 19 | 21 | 1,089 | 65 | 8 |
30 Jun 19 | 18 | 479 | 46 | 5 |
31 Mar 19 | 13 | 293 | 32 | 3 |
31 Dec 18 | 12 | -21 | 24 | 2 |
30 Sep 18 | 9 | -8 | 15 | 0 |
30 Jun 18 | 7 | -1 | 11 | 0 |
31 Mar 18 | 5 | -2 | 9 | 0 |
31 Dec 17 | 3 | -1 | 7 | 0 |
30 Sep 17 | 4 | 1 | 6 | 0 |
30 Jun 17 | 2 | 0 | 5 | 0 |
31 Mar 17 | 1 | -1 | 4 | 0 |
31 Dec 16 | 0 | -1 | 3 | 0 |
30 Sep 16 | 2 | 0 | 2 | 0 |
30 Jun 16 | 2 | 0 | 1 | 0 |
31 Mar 16 | 3 | 1 | 1 | 0 |
31 Dec 15 | 2 | 0 | 1 | 0 |
30 Sep 15 | 0 | -4 | 2 | 0 |
30 Jun 15 | -1 | -4 | 2 | 0 |
31 Mar 15 | -1 | -4 | 2 | 0 |
31 Dec 14 | -1 | -4 | 2 | 0 |
30 Sep 14 | 0 | -2 | 1 | 0 |
30 Jun 14 | 0 | -1 | 1 | 0 |
31 Dec 13 | 0 | -1 | 0 | 0 |
Quality Earnings: CRON is currently unprofitable.
Growing Profit Margin: CRON is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CRON is unprofitable, and losses have increased over the past 5 years at a rate of 54.2% per year.
Accelerating Growth: Unable to compare CRON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRON is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: CRON has a negative Return on Equity (-6.43%), as it is currently unprofitable.